The paradoxical role of methionine enkephalin in tumor responses

Area of Science:

• Immunology
• Oncology
• Neuroendocrinology

Background:

• Methionine enkephalin (MENK), an endogenous opioid peptide, plays significant roles in neuroregulation and immunoregulation.
• Tumors present a major challenge due to their aggressive nature and resistance to treatment.
• MENK's therapeutic potential in oncology is under investigation, with evidence suggesting both anti-tumor and pro-tumor activities.

Purpose of the Study:

• To review the dual roles of Methionine enkephalin (MENK) in cancer.
• To elucidate the mechanisms underlying MENK's anti-tumor and pro-tumor effects.
• To provide insights for optimizing MENK's application in cancer treatment.

Main Methods:

• Literature review of studies investigating MENK's effects on tumor responses.
• Analysis of MENK's impact on immune cells (T and B lymphocytes).
• Examination of MENK's direct effects on tumor cell proliferation and opioid receptor interactions.

Main Results:

• MENK demonstrates anti-tumor effects by enhancing immune responses and inhibiting tumor cell proliferation.
• Conversely, MENK can promote tumor progression by suppressing lymphocyte proliferation and facilitating tumor cell growth via opioid receptors.
• MENK binding to opioid receptors triggers dual reactions, influencing systemic anti-tumor immunity.

Conclusions:

• Methionine enkephalin (MENK) exhibits a complex, dual role in cancer biology.
• Its therapeutic application requires careful consideration of its opposing effects on the immune system and tumor cells.
• Further research is needed to harness MENK's anti-tumor potential while mitigating its pro-tumor effects for improved cancer therapies.